Alzheimer's Association Statement on FDA Decision to Hold Advisory Committee Meeting to Discuss Donanemab
March 09, 2024
March 09, 2024
CHICAGO, Illinois, March 9 -- The Alzheimer's Association issued the following statement on March 8, 2024:
* * *
The Alzheimer's Association appreciates the Food and Drug Administration's (FDA) thorough process in reviewing treatments for Alzheimer's disease. The FDA has determined it will hold an advisory committee meeting on donanemab (Lilly). While the decision is a surprise at this stage in the review process, the safety and appropriate administr . . .
* * *
The Alzheimer's Association appreciates the Food and Drug Administration's (FDA) thorough process in reviewing treatments for Alzheimer's disease. The FDA has determined it will hold an advisory committee meeting on donanemab (Lilly). While the decision is a surprise at this stage in the review process, the safety and appropriate administr . . .